Copenhagen, 13 November 2012 – Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) reports higher revenues from partner payments, a net profit and an increase in cash and securities combined with important progress for the company’s drug pipeline for the nine month period 1 January to 30 September 2012.
